Risankizumab is a drug of the anti-IL-23 family that shows a high effectiveness profile in real clinical practice, showing its robustness in different scenarios (obesity, bionaïvity, gender, and comorbidities) and without safety findings beyond those previously reported in the pivotal clinical trial. This evidence concerns the gene IL37 and Obesity.